Ultra Market Research | United Kingdom Gliolan Market
United Kingdom Gliolan Market
Report ID : 960
Category : Therapeutic-Area,United-Kingdom(UK)
No Of Pages : 99
Published on: January 2025
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United Kingdom Gliolan Market
Introduction United Kingdom Gliolan Market was estimated to be around £55 million in 2024. The market is expected to grow at a CAGR of 8.2% and reach £85 million by 2030. Gliolan is a fluorescence-guided imaging agent that is crucial in high-grade glioma surgeries, where neurosurgeons can differentiate tumor tissues from healthy tissues. The growing incidence of glioblastoma, which comprises more than 55% of primary malignant brain tumors in the UK, leads to the adoption of Gliolan. The evolving trend towards more state-of-the-art imaging technology and AI use in surgical workflows will only increase better patient outcomes. Furthermore, the NHS's focus on early diagnosis with access to cutting-edge surgical techniques adds momentum to the market.
Segmentation By Type • Surgical Applications o Glioblastoma Surgery Primary Resection Secondary Resection Others o Low-Grade Glioma Surgery Fluorescent-Guided Resection Non-Guided Resection • Diagnostics o Imaging Solutions Pre-Surgical Imaging Intraoperative Imaging • Others
By End-User • Hospitals o General Hospitals Public Private o Neurosurgery-Specific Hospitals • Specialty Clinics o Oncology Clinics o Neurosurgery Clinics • Ambulatory Surgical Centers
By Region • England o Greater London o South East England o North West England • Scotland o Central Belt o Highlands • Wales and Northern Ireland
List of Market Players 1. Photonamic GmbH & Co. KG (Germany) 2. Medac GmbH (Germany) 3. Carl Zeiss Meditec AG (Germany) 4. Zimmer Biomet (USA) 5. Medtronic Plc (Ireland) 6. Stryker Corporation (USA) 7. Olympus Corporation (Japan) 8. Boston Scientific Corporation (USA) 9. Leica Microsystems (Germany) 10. Varian Medical Systems (USA) 11. Elekta AB (Sweden) 12. GE Healthcare (USA) 13. Siemens Healthineers (Germany) 14. Brainlab AG (Germany) 15. Koninklijke Philips N.V. (Netherlands)
Drivers United Kingdom Gliolan Market is highly growth-oriented as the prevalence of high-grade gliomas continues to increase. Nearly 3,200 new cases of glioblastoma are reported in the UK each year. The efficiency of Gliolan with surgical precision largely reduces the chances of tumor recurrence. The rise in government support, such as the adoption of the NHS in advanced surgical practices and reimbursements of Gliolan-based procedures, helps to further boost market growth. The growing awareness among neurosurgeons about fluorescence-guided techniques contributes to the expansion. Private and public investment in healthcare infrastructure also supports adopting innovative surgical technologies.
Restraints Major obstacles facing the market are the high price of Gliolan, where one dose can be up to £600. Therefore, its use is relatively unaffordable for small-scale healthcare facilities. Limited reimbursement policies and specialized training in fluorescence-guided surgery limit its adoption. Furthermore, use of the device increases the operational costs, because of its requirement for special blue-light filters. Competition from alternative imaging techniques like intraoperative MRI and CT adds to the market's challenges.
Opportunity Opportunities in the United Kingdom Gliolan Market abound. There are opportunities to extend Gliolan applications to low-grade gliomas and other neurological conditions that currently lack appropriate diagnosis and treatment for underserved patient populations. A push for early diagnosis and better surgical outcomes within the NHS opens the way for market penetration. Potential partners in cost savings and access will be pharmaceutical companies and surgical device manufacturers. In addition, the incorporation of robotic-assisted surgeries in the treatment of high-grade glioma provides a platform for Gliolan to play a critical role in achieving precision and better post-operative results.
Trend United Kingdom Gliolan Market is shifting towards portable fluorescence-guided imaging devices, which makes the technology more accessible in smaller hospitals and clinics. Artificial intelligence integration is changing surgical workflows by providing real-time guidance during tumor resection. R&D efforts are aimed at improving Gliolan formulations to increase tumor selectivity and fluorescence intensity. Academic and industry collaborations are driving clinical trials for expanding the indications of Gliolan beyond glioblastomas.
Approved Products and Pipeline • Approved Products: Gliolan (5-aminolevulinic acid hydrochloride) • Pipeline Products: Advanced formulations for multi-modal imaging, Pre-reg products for pediatric applications
Key Target Audience • Neurosurgeons • Hospitals and Healthcare Systems • Ambulatory Surgical Centers • Oncology and Neurosurgery Clinics • Academic and Research Institutions • Medical Device Manufacturers • Policy Makers and Regulators
Frequently Asked Questions (FAQ's)
As of 2024, the market is valued at £55 million.
Increasing glioblastoma cases and the adoption of fluorescence-guided surgery are key drivers.
High costs, limited reimbursement policies, and the need for specialized training pose challenges.
AI integration, portable imaging devices, and expanding Gliolan applications are significant trends.
Photonamic GmbH, Carl Zeiss Meditec AG, and Medac GmbH are prominent players.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis
2. Market Dashboard
3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Type • Surgical Applications o Glioblastoma Surgery Primary Resection Secondary Resection Others o Low-Grade Glioma Surgery Fluorescent-Guided Resection Non-Guided Resection • Diagnostics o Imaging Solutions Pre-Surgical Imaging Intraoperative Imaging • Others 3.2.2 By End-User • Hospitals o General Hospitals Public Private o Neurosurgery Hospitals • Specialty Clinics o Oncology Clinics o Neurosurgery Clinics • Ambulatory Surgical Centers 3.2.3 By Region • England o Greater London o South East England o North West England • Scotland o Central Belt o Highlands • Wales and Northern Ireland 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges
4. United Kingdom Gliolan Market by Type 4.1 Introduction 4.2 Market Size and Growth Rate by Type (2024–2030) 4.2.1 Surgical Applications • Glioblastoma Surgery o Primary Resection o Secondary Resection • Low-Grade Glioma Surgery o Fluorescent-Guided Resection 4.2.2 Diagnostics • Pre-Surgical Imaging • Intraoperative Imaging
5. United Kingdom Gliolan Market by End-User 5.1 Introduction 5.2 Market Size and Growth Rate by End-User (2024–2030) 5.2.1 Hospitals • General Hospitals • Neurosurgery Hospitals 5.2.2 Specialty Clinics • Oncology Clinics • Neurosurgery Clinics 5.2.3 Ambulatory Surgical Centers
6. United Kingdom Gliolan Market by Region 6.1 Introduction 6.2 Market Size and Growth Rate by Region (2024–2030) 6.2.1 England • Greater London • South East England • North West England 6.2.2 Scotland • Central Belt • Highlands 6.2.3 Wales and Northern Ireland
9. Appendix 9.1 List of Tables • Table 1: Market Segmentation Overview • Table 2: Market Size by Type (2024–2030) • Table 3: Market Size by End-User (2024–2030) • Table 4: Market Size by Region (2024–2030)
9.2 List of Figures • Figure 1: United Kingdom Gliolan Market Growth Rate (2024–2030) • Figure 2: Market Share by Type (2024) • Figure 3: Market Share by End-User (2024) • Figure 4: Market Share by Region (2024)
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of United Kingdom market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United Kingdom Gliolan Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of United Kingdom Gliolan Market for the past year and forecasts for the next six years. United Kingdom Gliolan Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United Kingdom Gliolan Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for United Kingdom Gliolan Market from different application industries in different regions.
Segmentation By Type • Surgical Applications o Glioblastoma Surgery Primary Resection Secondary Resection Others o Low-Grade Glioma Surgery Fluorescent-Guided Resection Non-Guided Resection • Diagnostics o Imaging Solutions Pre-Surgical Imaging Intraoperative Imaging • Others
By End-User • Hospitals o General Hospitals Public Private o Neurosurgery-Specific Hospitals • Specialty Clinics o Oncology Clinics o Neurosurgery Clinics • Ambulatory Surgical Centers
By Region • England o Greater London o South East England o North West England • Scotland o Central Belt o Highlands • Wales and Northern Ireland
